ERBB2 and neoplasm: It is likely that no improvement in overall survival following the addition of anti-HER2 in the adjuvant setting could be reported since the patients included were at low risk for tumour recurrence [11]; more than 77% of the patients included had a pT1 tumour, and almost 30% had a pT1a tumour.